|
09 Feb 2012
HOME
Pharma/CDC on Brain
damage from vaccines, Fauci, Phages, Bioweapons manufacture
HHS.gov is
Incompetent; BMJ calls fraud "crime.")
Official: CFIDS and MS-Lyme are the
same disease; Epstein-Barr
CDC Greed
(won't answer the FOIA)
ELISA = arbitrary cutoff.
Disclaimer
Overview
TUSKEGEE - By Jerry Leonard
1998, CIA Oilmen & Israelis plan to overthrow
Saddam for the oil.
Bush/Gore Oil/War-(Oct,2000)
Bush's own explainer (Oct
2000):
Iraq Oil
Iraq was an oil-theft war.
| |
DSM-IV Dole-Bayh Act Disease:
A psychosis related to the chronic defiance over
having been exposed as a total fraud, from the Dearborn Hoax (Steere
in Europe), to "Lyme Disease" (a bad knee that "goes
away on its own in 4 years" without any treatment), to
Magically
Readable Unreadable Western Blots (Weinsteinium
and
Crooked Sour OspA Grapes), to
the Negative Data Rule.
This illness is similar to Borderline Personality
Disorder (Drama Queens) in that the sufferers of the disease
reliably throw in hysterical fits
whenever confronted with their own conflicting statements.
Example: Yale's Durland Fish' Hit List:
2007 Fish Hysterical and hysterical comments to the Hartford Courant
interviewer.
The Treatment is to get Durland Fish out of the
Plum Island Lab, by
removing 1) Plum Island from Yale's management, 2) completely de-funding
Yale's Bumbling by giving out over a billion dollars worth of grants to
everyone university lab group except Yale, 3) sending the
CT Attorney General up their
butts, 4) giving out the $500,000 Albany Award to the people who
really
understood immunology, and 5) recognizing Paul Duray who discovered the
lymphocyte mutations in chronic Lyme victims and reported it to Yale et
al in 1989 and
1992.
Otherwise, just ignore them and move on with the new discovery,
MALP-2, which will do what OspA did but not with the harmful effects such as causing Chronic Lyme (or the
immune-suppression-related New Great Imitators or the New
Yuppie AIDS or being "the Perfect
Stealth Disabler" or the Trojan Horse Disease).
"It is well known that
Borrelia burgdorferi indeed after asymptomatic infection can lurk or
secrete itself in certain areas of the body, perhaps the central
nervous system or perhaps the joint spaces, only to reappear months
or maybe years later in the form of late stages of illness which are
harder to diagnosis and treat.
-- Vijay Sikand, 1998 FDA OspA or LYMErix
Vaccine Meeting.
======================================================
Allen Steere et al treating Lyme long-term because it is of
benefit
Crooked Sour OspA Grapes & Guidelines from Valhella (◄You can't
make this stuff up.)
The Big Enders and the Little Enders had a dispute about
unreadable Western Blots... but who pissed on their
OspA fire?
And what did these intellectual Lilliputians miss out on?

090618.htm
When people begin to realize that the association
between OspA-like-induced or fungal immunosuppression and vaccines
extends to the parallel epidemics of asthma and autism in children (the
former is hypersensitivity and the latter is the opposite), then they'll
be interested in "Lyme Disease":
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=17265454[uid]
Lipopolysaccharide Binding Protein Binds to
Triacylated and Diacylated Lipopeptides and Mediates Innate Immune Responses1
http://www.jimmunol.org/cgi/content/full/173/4/2683
"Lipoproteins and lipopeptides have been
identified in a large number of microorganisms, the most
prominent ones being mycobacteria, mycoplasms, and spirochetes.
They have been found to exhibit both a strong innate inflammatory
response in the host and an enduring adaptive immune response in
mammalian hosts (16).
The strong proinflammatory capacities of lipoproteins were first
described for outer surface proteins A and B of
Borrelia burgdorferi, which are also highly
immunogenic (17)
and have lately been the basis for a Lyme disease vaccine
development (18).
These compounds exhibit an triacylated lipid anchor structure
comprising an N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl
(Pam3Cys) moiety at the N terminus (19),
a feature that was previously described for the Braun lipoprotein
from Escherichia coli (20).
Because the N-terminal Pam3Cys modification is essential
for immunoactivation caused by lipoproteins of B. burgdorferi
as well as of another spirochete, Treponema pallidum
(21),
subsequent studies investigating immune responses to spirochetes
used synthetic lipopeptides (22).
The Pam3Cys moiety was also reported to be present
in cytokine-inducing lipoproteins of Mycobacterium and
Mycoplasma spp. (23,
24);
thus, it can be regarded as a highly conserved molecular motif
among different classes of bacteria. In Mycoplasma fermentans,
the presence of a macrophage stimulating lipopeptide, termed
2-kDa macrophage-activating lipopeptide (MALP-2), was observed,
being stimulatory active at picomolar concentrations (25).
This compound, in contrast to the predominant lipopeptide
structures present in lipoproteins of E. coli, B. burgdorferi,
and mycobacteria, lacks the N-palmitoyl group, thus containing a
diacylated (Pam2Cys) lipid anchor structure at the
N terminus. Following studies revealed the presence of closely
related compounds in other Mycoplasma spp. (26).."
Toll-like receptor 2-dependent inhibition of macrophage
class II MHC expression and antigen processing by 19-kDa lipoprotein of
Mycobacterium tuberculosis.
Department of
Pathology, Case Western Reserve University and University Hospitals of
Cleveland, Cleveland, OH 44106, USA.
Noss EH,
Pai RK,
Sellati TJ,
Radolf JD,
Belisle J,
Golenbock DT,
Boom WH,
Harding CV.
Mycobacterium tuberculosis (MTB) induces vigorous immune
responses, yet persists inside macrophages, evading host immunity. MTB bacilli
or lysate was found to inhibit macrophage expression of class II MHC (MHC-II)
molecules and MHC-II Ag processing. This report characterizes and identifies a
specific component of MTB that mediates these inhibitory effects. The inhibitor
was extracted from MTB lysate with Triton X-114, isolated by gel electroelution,
and identified with Abs to be MTB 19-kDa lipoprotein. Electroelution- or
immunoaffinity-purified MTB 19-kDa lipoprotein inhibited MHC-II expression and
processing of both soluble Ags and Ag 85B from intact MTB bacilli. Inhibition
of MHC-II Ag processing by either MTB bacilli or purified MTB 19-kDa lipoprotein
was dependent on Toll-like receptor (TLR) 2 and independent of TLR 4.
Synthetic analogs of lipopeptides from Treponema pallidum also inhibited Ag
processing. Despite the ability of MTB 19-kDa lipoprotein to activate
microbicidal and innate immune functions early in infection, TLR 2-dependent
inhibition of MHC-II expression and Ag processing by MTB 19-kDa lipoprotein
during later phases of macrophage infection may prevent presentation of MTB Ags
and decrease recognition by T cells. This mechanism may allow intracellular MTB
to evade immune surveillance and maintain chronic infection.
Department of Medicine, New York Medical College,
Valhalla, NY 10595, USA.
The modulation of human lymphocyte proliferative
responses was demonstrated with a recombinant outer surface protein A (OspA)
vaccine preparation for the prevention of Borrelia burgdorferi infection. After
exposure to either the unaltered vaccine preparation or OspA prepared in saline,
normal lymphocyte responses to the mitogens concanavalin A, phytohemagglutinin-M
or pokeweed mitogen, or the antigen BCG were consistently reduced. Whole cell
extracts of B. burgdorferi also modulated immune responses but required a much
greater quantity of protein than needed for the OspA preparation. The magnitude
of modulation was directly dependent on the quantity of OspA. OspA interferes
with the response of lymphocytes to proliferative stimuli including a blocking
of cell cycle phase progression. Future studies designed to delete the
particular region or component of the OspA molecule responsible for this effect
may lead to improved vaccine preparations.
|